July 7, 2021

Scorpion Therapeutics Announces New CEO Axel Hoos, M.D., Ph.D.

BOSTON, MA. — July 7, 2021 — Scorpion Therapeutics, Inc., a next-generation oncology company developing best- and first-in-class precision medicines for cancer patients, today announced that...

Boston, MA  |   April 8, 2021

Scorpion Therapeutics Appoints Guy Padbury, Ph.D. as Chief Development Officer

BOSTON — April 8, 2021 — Scorpion Therapeutics, Inc., a next-generation precision oncology company, today announced the appointment of Guy Padbury, Ph.D. as Chief Development Officer....

February 25, 2021

Scorpion Therapeutics Announces Leadership Change

– Board Appoints Adam Friedman, M.D., Ph.D., as Interim CEO –  Scorpion Therapeutics announced that Adam Friedman, M.D., Ph.D., has been appointed Chief Executive Officer on an interim basis. The Board of Directors is currently evaluating...


STAT (Subscription Required)   |   July 9, 2021

Scorpion Therapeutics hired Axel Hoos as chief executive officer. Previously, he worked at GlaxoSmithKline, where he was senior vice president of R&D governance chair and therapeutic area...

Boston Business Journal   |   July 9, 2021

Just eight months out of stealth, precision medicine startup Scorpion Therapeutics has netted a big fish in Axel Hoos, the head of oncology at GlaxoSmithKline plc,...

Scrip (Subscription Required)   |   July 7, 2021

Axel Hoos will become the CEO of a Boston-based cancer start-up focusing on targeted precision drugs. He talked to Scrip about the decision to leave GSK after 10...

BioCentury (Subscription Required)   |   July 7, 2021

GSK is losing one of the principal architects of its oncology renaissance as immuno-oncology pioneer Axel Hoos prepares to leave the company for his first CEO...

Fierce Biotech   |   July 7, 2021

After leading oncology teams at GlaxoSmithKline and Bristol Myers Squibb, Axel Hoos, M.D., Ph.D., is heading back to biotech.  

Endpoints   |   July 7, 2021

Axel Hoos has long kept the flame alive at GlaxoSmithKline’s oncology division, enduring lean days after the British pharma ditched its late-stage pipeline to Novartis and...

Fierce Biotech   |   January 12, 2021

Less than three months after breaking cover with an impressive $102 million series A, Scorpion has whipped up another major funding round, nabbing $162 million for its next-gen cancer drugs.

Boston Globe   |   January 12, 2021

Just over two months after announcing its debut with $108 million in funding, Boston startup Scorpion Therapeutics said Thursday it has raised an even larger amount of venture capital.

Endpoints News   |   January 12, 2021

Whatever investors have peeped about Gary Glick and Keith Flaherty’s game plan to bring about Precision Oncology 2.0, it’s good enough for a $162 million infusion into Scorpion Therapeutics just weeks after its $108 million Series A.

Fierce Biotech   |   October 26, 2020

When Gary Glick, Ph.D., left the CEO post at IFM Therapeutics, he didn’t know what was next. But he soon found himself on a plane with Loxo Oncology co-founder Keith Flaherty, and they got to talking about how they could “expand the boundaries of targeted oncology.”


J.P. Morgan 39th Annual Healthcare Conference   |   January 13, 2021

Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.

Media Contact
Ravi Moorthy